Karuna Therapeutics Executive Compensation (FY22)

Name: Karuna Therapeutics (KRTX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

KRTX · Executive and director compensation, fiscal 2022 only

The paid brief on Karuna Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of September 7, 2026Latest filing (DEF 14A): April 27, 2023

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Karuna Therapeutics brief$1,500Get the executive brief

102 figures on this page, cited to the filing that reported them. See the citations

Chief executive, fiscal 2022

◇

Steven Paul

Chief executive pay ratio

◇

To the median employee

Frequently asked questions

Answers drawn from the data on this page.

Who is Karuna Therapeutics' chief executive and what were they paid?

Steven Paul, President and Chief Executive Officer, received $11,224,103 in total compensation for fiscal 2022.

Which companies are in Karuna Therapeutics' peer group?

Companies named in the disclosed peer group include Acadia Pharmaceuticals Inc., Alector, Inc., Allakos Inc., Apellis Pharmaceuticals, Inc. and Arvinas, Inc., among others.

What is Karuna Therapeutics' chief executive pay ratio?

The disclosed chief executive pay ratio for fiscal 2022 is 27:1.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Steven Paul President and Chief Executive Officer	◇	—	—	◇	◇	—	◇	◇
Andrew Miller Chief Operating Officer	◇	—	—	◇	◇	—	◇	◇
Stephen Brannan Chief Medical Officer	◇	—	—	◇	◇	—	◇	◇
Troy Ignelzi Chief Financial Officer	◇	—	—	◇	◇	—	◇	◇
Charmaine Lykins Chief Commercial Officer	◇	—	—	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2022

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Andrew Miller	OPTION	◇	—	—	◇	—	◇	◇
Stephen Brannan	OPTION	◇	—	—	◇	—	◇	◇
Steven Paul	OPTION	◇	—	—	◇	—	◇	◇
Troy Ignelzi	OPTION	◇	—	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2022 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Steven Paul	Option	◇	—	◇	2/13/2030
	Option	◇	—	◇	2/22/2031
	Option	◇	—	◇	2/15/2032
Troy Ignelzi	Option	◇	—	◇	2/13/2030
	Option	◇	—	◇	3/21/2029
	Option	◇	—	◇	2/22/2031
	Option	◇	—	◇	2/15/2032
Andrew Miller	Option	◇	—	◇	2/13/2030
	Option	◇	—	◇	2/15/2032
	Option	◇	—	◇	2/22/2031
Stephen Brannan	Option	◇	—	◇	2/22/2031
	Option	◇	—	◇	3/20/2029
	Option	◇	—	◇	2/13/2030
	Option	◇	—	◇	2/15/2032
Charmaine Lykins	Option	◇	—	◇	11/28/2031

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.

Fiscal 2022

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Christopher J. Coughlin Board chair	◇	—	◇	—	—	◇	◇
Laurie Olson	◇	—	◇	—	—	—	◇
Atul Pande, M.D	◇	—	◇	—	—	—	◇
James Healy, M.D., Ph.D	◇	—	◇	—	—	—	◇
Denice Torres	◇	—	◇	—	—	—	◇
David Wheadon, M.D	◇	—	◇	—	—	—	◇
Jeffrey Jonas, M.D	◇	—	◇	—	—	—	◇

Steven Paul, M.D and Bill Meury served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Lead independent director premium	◇
Audit committee chair	◇
Compensation committee chair	◇
Nominating and governance chair	◇

Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2022

Acadia Pharmaceuticals Inc. ACAD
Alector, Inc. ALEC
Allakos Inc. ALLK
Apellis Pharmaceuticals, Inc. APLS
Arvinas, Inc. ARVN
Axsome Therapeutics, Inc. AXSM
Biohaven Pharmaceutical Holding Company Ltd. symbol not shown
BioXcel Therapeutics, Inc. BTAI
Cerevel Therapeutics Holdings, Inc. CERE
Cortexyme, Inc. symbol not shown
Denali Therapeutics Inc. DNLI
Intra-Cellular Therapies, Inc. ITCI
Kodiak Sciences Inc. KOD
Mirati Therapeutics, Inc. MRTX
Prothena Corporation plc PRTA
Rhythm Pharmaceuticals, Inc. RYTM
Sage Therapeutics, Inc. SAGE
TG Therapeutics, Inc. TGTX

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Chief executive total compensation

◇

What this page does not include

Everything above is a fact Karuna Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Karuna Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $1,200

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

102 figures on this page, cited to the filing that reported them.

102 cited to the filing

Documents cited

DEF 14A, filed April 27, 2023
0000950170-23-014979
CEO Pay Ratio · Director Compensation in 2022 · Grants of Plan-Based Awards for Fiscal Year 2022 · Outstanding equity awards at December 31, 2022 · and 1 more section

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Karuna Therapeutics executive compensation, FY2022.” https://intel.velarion.ai/comp/KRTX (accessed 2026).

Short form: data: Velarion

The paid brief for Karuna Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/KRTX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Karuna Therapeutics executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Karuna Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Peers Karuna Therapeutics discloses

The companies named in KRTX's own disclosed peer group.

Acadia Pharmaceuticals Inc.Alector, Inc.Allakos Inc.Apellis Pharmaceuticals, Inc.Arvinas, Inc.Axsome Therapeutics, Inc.Cerevel Therapeutics Holdings, Inc.Denali Therapeutics Inc.Intra-Cellular Therapies, Inc.Kodiak Sciences Inc.Prothena Corporation plc Rhythm Pharmaceuticals, Inc.Sage Therapeutics, Inc.TG Therapeutics, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Karuna Therapeutics

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Director compensation

Director fee schedule

Disclosed peer group

Chief executive pay ratio

What this page does not include

Citations

Documents cited

The paid brief for Karuna Therapeutics

Peers Karuna Therapeutics discloses

Terms on this page